Christine Roder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christine Roder has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Amanda J. Wade
Barwon Health Geelong Victoria Australia
3 shared publications - Carl Cosgrave
Gastroenterology Department, Barwon Health, Geelong 3220, Australia
2 shared publications Eugene Athan
Barwon Health Geelong VIC
2 shared publications- Eugene Athan
Department of Infectious Diseases, Barwon Health , Geelong, Victoria
2 shared publications - Joseph Samuel Doyle
Department of Infectious Diseases The Alfred and Monash University Melbourne Victoria Australia
2 shared publications - Kathryn Mackie
Pharmacy Department, Barwon Health, Geelong 3220, Australia
2 shared publications
Latest Publications
- Open Access
Missed Opportunities: A Retrospective Study of Hepatitis C Testing in Hospital Inpatients
Increasing testing is key to achieving hepatitis C elimination. This retrospective study aimed to assess the testing cascade of patients at a regional hospital in Victoria, Australia, who inject drugs or are living with hepatitis C, to identify missed opportunities for hepatitis C care. Adult hospital inpatients and emergency department (ED) attendees from 2018 to 2021 with indications for intravenous drug use (IDU) or hepatitis C on their discharge or ED summary were included. Data sources: hospital admissions, pathology, hospital pharmacy, and outpatients. We assessed progression through the testing cascade and performed logistic regression analysis for predictors of hepatitis C care, including testing and treatment. Of 79,923 adults admitted, 1345 (1.7%) had IDU-coded separations and 628 (0.8%) had hepatitis C-coded separations (N = 1892). Hepatitis C virus (HCV) status at the end of the study was unknown for 1569 (82.9%). ED admissions were associated with increased odds of not providing hepatitis C care (odds ratio 3.29, 95% confidence interval 2.42–4.48). More than 2% of inpatients at our hospital have an indication for testing, however, most are not being tested despite their hospital contact. As we work toward HCV elimination in our region, we need to incorporate testing and linkage strategies within hospital departments with a higher prevalence of people at risk of infection.
Open AccessMissed Opportunities: A Retrospective Study of Hepatitis C Testing in Hospital Inpatients
Increasing testing is key to achieving hepatitis C elimination. This retrospective study aimed to assess the testing cascade of patients at a regional hospital in Victoria, Australia, who inject drugs or are living with hepatitis C, to identify missed opportunities for hepatitis C care. Adult hospital inpatients and emergency department (ED) attendees from 2018 to 2021 with indications for intravenous drug use (IDU) or hepatitis C on their discharge or ED summary were included. Data sources: hospital admissions, pathology, hospital pharmacy, and outpatients. We assessed progression through the testing cascade and performed logistic regression analysis for predictors of hepatitis C care, including testing and treatment. Of 79,923 adults admitted, 1345 (1.7%) had IDU-coded separations and 628 (0.8%) had hepatitis C-coded separations (N = 1892). Hepatitis C virus (HCV) status at the end of the study was unknown for 1569 (82.9%). ED admissions were associated with increased odds of not providing hepatitis C care (odds ratio 3.29, 95% confidence interval 2.42–4.48). More than 2% of inpatients at our hospital have an indication for testing, however, most are not being tested despite their hospital contact. As we work toward HCV elimination in our region, we need to incorporate testing and linkage strategies within hospital departments with a higher prevalence of people at risk of infection.
- Open Access
Leave No-One Behind: A Retrospective Study of Hepatitis C Testing and Linkage to Care for Hospital Inpatients
Hospital admissions are a missed opportunity to engage people living with hepatitis C virus (HCV) into care. This study aimed to describe the proportion of hospital inpatients and emergency department (ED) patients identified with hepatitis C who were subsequently linked to care and treatment at a metropolitan health service in Melbourne, Australia. Data were collected retrospectively from hospital databases (admissions, notifiable diseases, and pharmacy) for all adults admitted or attending the ED with separation coding indicating hepatitis C infection from March 2016 to March 2019. There were 2149 patients with at least one separation with hepatitis C coding. 15.4% (331/2149) had a documented antibody test, 4.6% (99/2149) had a documented RNA test, and 8.3% (179/2149) had a DAA prescription dispensed by hospital pharmacy. Antibody positivity was 95.2% (315/331) and RNA (when completed) was detected in 37.4% (37/99). Hepatitis specialist units had the highest rate of hepatitis C coded separations and RNA testing (39/88; 44.3%), mental health had the highest rate of antibody testing (70/276; 25.4%). Emergency had the lowest rate of antibody testing (101/1075; 13.7%) and the third highest rate of RNA testing (32/94; 34.1%), but the highest rate of RNA detected (15/32; 46.9%). This study highlights key steps to improve the care cascade. Simplified diagnostic pathways, expansion of hepatitis C care services, and clear in-hospital pathways to link patients to care would be beneficial in this setting. To scale up hepatitis C testing and treatment as part of national elimination strategies, hospital systems need to target interventions to their local data.
Open AccessLeave No-One Behind: A Retrospective Study of Hepatitis C Testing and Linkage to Care for Hospital Inpatients
Hospital admissions are a missed opportunity to engage people living with hepatitis C virus (HCV) into care. This study aimed to describe the proportion of hospital inpatients and emergency department (ED) patients identified with hepatitis C who were subsequently linked to care and treatment at a metropolitan health service in Melbourne, Australia. Data were collected retrospectively from hospital databases (admissions, notifiable diseases, and pharmacy) for all adults admitted or attending the ED with separation coding indicating hepatitis C infection from March 2016 to March 2019. There were 2149 patients with at least one separation with hepatitis C coding. 15.4% (331/2149) had a documented antibody test, 4.6% (99/2149) had a documented RNA test, and 8.3% (179/2149) had a DAA prescription dispensed by hospital pharmacy. Antibody positivity was 95.2% (315/331) and RNA (when completed) was detected in 37.4% (37/99). Hepatitis specialist units had the highest rate of hepatitis C coded separations and RNA testing (39/88; 44.3%), mental health had the highest rate of antibody testing (70/276; 25.4%). Emergency had the lowest rate of antibody testing (101/1075; 13.7%) and the third highest rate of RNA testing (32/94; 34.1%), but the highest rate of RNA detected (15/32; 46.9%). This study highlights key steps to improve the care cascade. Simplified diagnostic pathways, expansion of hepatitis C care services, and clear in-hospital pathways to link patients to care would be beneficial in this setting. To scale up hepatitis C testing and treatment as part of national elimination strategies, hospital systems need to target interventions to their local data.
- 28 February 2022
- Published by Wiley in Medical Journal of Australia
- Vol. 216 (7) , 349-356
Area‐level social and economic factors and the local incidence of SARS‐CoV‐2 infections in Victoria during 2020
To examine associations between area‐level socio‐economic factors and the incidence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infections in Victoria during 2020. Population‐level ecological study of the incidence of SARS‐CoV‐2 infections in Victoria, by postcode, 1 March ‒ 13 August 2020. Relationships between the incidence of SARS‐CoV‐2 infections by postcode (Department of Health and Human Services data published on The Age website), and demographic, education level, ethnic background, economic and employment‐related factors, housing‐related factors, and social disadvantage (Australian Bureau of Statistics data for 2014–19), expressed as incidence rate ratios (IRRs). During the study period, 15 482 SARS‐CoV‐2 infections with associated postcodes were recorded in Victoria. Incidence was higher for metropolitan than regional postcodes (418.3 v 62 infections per 100 000 population; IRR, 6.2; 95% CI, 4.6–8.2). In regional postcodes, incidence rose with mean household size (per person: IRR, 7.30; 95% CI, 4.37–12.2), unemployment proportion (per percentage point: IRR, 1.50; 95% CI, 1.33–1.69), and proportions for whom rent (IRR, 1.15; 95% CI, 1.07–1.22) or mortgage repayments (IRR, 1.22; 95% CI, 1.15–1.28) exceeded 30% of household income. In metropolitan areas, incidence increased with unemployment proportion (IRR, 1.14; 95% CI, 1.05–1.23) and proportion without paid leave (IRR, 1.22; 95% CI, 1.02–1.45). Incidence also increased with proportion speaking languages other than English at home (regional: IRR, 1.08; 95% CI, 1.06–1.11; metropolitan: IRR, 1.01; 95% CI, 1.002–1.02) and with Indigenous Australian proportion (metropolitan only: IRR, 1.91; 95% CI, 1.10–2.73). Socio‐economic factors may have contributed to the non‐homogeneous incidence of SARS‐CoV‐2 infections across Victoria during 2020.
- 28 February 2022
- Published by Wiley in Medical Journal of Australia
- Vol. 216 (7) , 349-356
Area‐level social and economic factors and the local incidence of SARS‐CoV‐2 infections in Victoria during 2020
To examine associations between area‐level socio‐economic factors and the incidence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infections in Victoria during 2020. Population‐level ecological study of the incidence of SARS‐CoV‐2 infections in Victoria, by postcode, 1 March ‒ 13 August 2020. Relationships between the incidence of SARS‐CoV‐2 infections by postcode (Department of Health and Human Services data published on The Age website), and demographic, education level, ethnic background, economic and employment‐related factors, housing‐related factors, and social disadvantage (Australian Bureau of Statistics data for 2014–19), expressed as incidence rate ratios (IRRs). During the study period, 15 482 SARS‐CoV‐2 infections with associated postcodes were recorded in Victoria. Incidence was higher for metropolitan than regional postcodes (418.3 v 62 infections per 100 000 population; IRR, 6.2; 95% CI, 4.6–8.2). In regional postcodes, incidence rose with mean household size (per person: IRR, 7.30; 95% CI, 4.37–12.2), unemployment proportion (per percentage point: IRR, 1.50; 95% CI, 1.33–1.69), and proportions for whom rent (IRR, 1.15; 95% CI, 1.07–1.22) or mortgage repayments (IRR, 1.22; 95% CI, 1.15–1.28) exceeded 30% of household income. In metropolitan areas, incidence increased with unemployment proportion (IRR, 1.14; 95% CI, 1.05–1.23) and proportion without paid leave (IRR, 1.22; 95% CI, 1.02–1.45). Incidence also increased with proportion speaking languages other than English at home (regional: IRR, 1.08; 95% CI, 1.06–1.11; metropolitan: IRR, 1.01; 95% CI, 1.002–1.02) and with Indigenous Australian proportion (metropolitan only: IRR, 1.91; 95% CI, 1.10–2.73). Socio‐economic factors may have contributed to the non‐homogeneous incidence of SARS‐CoV‐2 infections across Victoria during 2020.
- 28 September 2021
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 28 (12) , 1763-1764
Psychiatrists can treat hepatitis C
- 28 September 2021
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 28 (12) , 1763-1764
Psychiatrists can treat hepatitis C
- 1 July 2020
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 29 (7) , e140-e146
Cost and Outcomes of Implantable Cardiac Electronic Device Infections in Victoria, Australia
- 1 July 2020
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 29 (7) , e140-e146
Cost and Outcomes of Implantable Cardiac Electronic Device Infections in Victoria, Australia
- Open Access
- 6 May 2020
- Published by Springer Nature in Drugs in R&D
- Vol. 20 (3) , 209-216
In Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection
Background Clostridium difficile infection is the leading cause of hospital-acquired gastrointestinal infection and incidence rates continue to rise. Clostridium difficile infection is becoming increasingly complex to treat owing to the rise in treatment failures and recurrent infections. There is a clear need for new therapeutic options for the management of this disease. Objective This study aimed to assess auranofin, a drug approved for the treatment of arthritis, as a treatment for C. difficile infection. Previous investigations have demonstrated potential antimicrobial activity of auranofin against C. difficile and other organisms. Methods The activity of auranofin was assessed by in vitro investigations of its effect on C. difficile M7404 growth, vegetative cell viability, and spore viability. Activity of auranofin was also compared to that of the current treatments, metronidazole and vancomycin. Results Auranofin showed bactericidal activity at concentrations as low as 4.07 µg/mL, effectively reducing bacterial cell density by 50–70% and the viable vegetative cell and spore yields by 100%. The activity of auranofin was shown to be non-inferior to that of metronidazole and vancomycin. Conclusions Auranofin is highly efficacious against C. difficile M7404 in vitro and has the potential to be an ideal therapeutic option for the treatment of C. difficile infection.
- 6 May 2020
- Published by Springer Nature in Drugs in R&D
- Vol. 20 (3) , 209-216
Open AccessIn Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection
Background Clostridium difficile infection is the leading cause of hospital-acquired gastrointestinal infection and incidence rates continue to rise. Clostridium difficile infection is becoming increasingly complex to treat owing to the rise in treatment failures and recurrent infections. There is a clear need for new therapeutic options for the management of this disease. Objective This study aimed to assess auranofin, a drug approved for the treatment of arthritis, as a treatment for C. difficile infection. Previous investigations have demonstrated potential antimicrobial activity of auranofin against C. difficile and other organisms. Methods The activity of auranofin was assessed by in vitro investigations of its effect on C. difficile M7404 growth, vegetative cell viability, and spore viability. Activity of auranofin was also compared to that of the current treatments, metronidazole and vancomycin. Results Auranofin showed bactericidal activity at concentrations as low as 4.07 µg/mL, effectively reducing bacterial cell density by 50–70% and the viable vegetative cell and spore yields by 100%. The activity of auranofin was shown to be non-inferior to that of metronidazole and vancomycin. Conclusions Auranofin is highly efficacious against C. difficile M7404 in vitro and has the potential to be an ideal therapeutic option for the treatment of C. difficile infection.